|
1
|
Nthumba PM: Osteosarcoma of the jaws: A
review of literature and a case report on synchronous multicentric
osteosarcomas. World J Surg Oncol. 10:2402012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertucci F, Araujo J and Giovannini M:
Pancreatic metastasis from osteosarcoma and Ewing sarcoma:
Literature review. Scand J Gastroenterol. 48:4–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fayda M, Kebudi R, Dizdar Y, Gorgun O, Gun
F, Aksu G and Ayan I: Spontaneous pneumothorax in children with
osteosarcoma: Report of three cases and review of the literature.
Acta Chir Belg. 112:378–381. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
He H, Ni J and Huang J: Molecular
mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett.
7:1352–1362. 2014.PubMed/NCBI
|
|
5
|
Haddox CL, Han G, Anijar L, Binitie O,
Letson GD, Bui MM and Reed DR: Osteosarcoma in pediatric patients
and young adults: A single institution retrospective review of
presentation, therapy, and outcome. Sarcoma. 2014:4025092014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
PosthumaDeBoer J, Witlox MA, Kaspers GJ
and van Royen BJ: Molecular alterations as target for therapy in
metastatic osteosarcoma: A review of literature. Clin Exp
Metastasis. 28:493–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Springfield DS, Schakel ME Jr and Spanier
SS: Spontaneous necrosis in osteosarcoma. Clin Orthop Relat Res.
1–237. 1991.
|
|
8
|
He JP, Hao Y, Wang XL, Yang XJ, Shao JF,
Guo FJ and Feng JX: Review of the molecular pathogenesis of
osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sami SH, Rafati AH and Hodjat P: Tissue
necrosis after chemotherapy in osteosarcoma as the important
prognostic factor. Saudi Med J. 29:1124–1129. 2008.PubMed/NCBI
|
|
10
|
Song WS, Jeon DG, Cho WH, Kong CB, Cho SH
and Lee SY and Lee SY: Spontaneous necrosis and additional tumor
necrosis induced by preoperative chemotherapy for osteosarcoma: A
case-control study. J Orthop Sci. 20:174–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li X, Ashana AO, Moretti VM and Lackman
RD: The relation of tumour necrosis and survival in patients with
osteosarcoma. Int Orthop. 35:1847–1853. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kato H, Wakabayashi H, Naito Y, Kato S,
Nakagawa T, Matsumine A and Sudo A: Anti-tumor necrosis factor
therapy inhibits lung metastasis in an osteosarcoma cell line.
Oncol. 88:139–146. 2015. View Article : Google Scholar
|
|
13
|
Gorlick R and Meyers PA: Osteosarcoma
necrosis following chemotherapy: Innate biology versus
treatment-specific. J Pediatr Hematol Oncol. 25:840–841. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martinotti S, Patrone M, Manfredi M,
Gosetti F, Pedrazzi M, Marengo E and Ranzato E: HMGB1
osteo-modulatory action on osteosarcoma SaOS-2 cell line: An
integrated study from biochemical and -Omics approaches. J Cell
Biochem. 117:2559–2569. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang J, Ni J, Liu K, Yu Y, Xie M, Kang R,
Vernon P, Cao L and Tang D: HMGB1 promotes drug resistance in
osteosarcoma. Cancer Res. 72:230–238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu T, Zhang W, Yang G, Li H, Chen Q, Song
R and Zhao L: HMGB1 overexpression as a prognostic factor for
survival in cancer: A meta-analysis and systematic review.
Oncotarget. 7:50417–50427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X, Wang S, Chen Y, Liu G and Yang X:
miR-22 targets the 3′UTR of HMGB1 and inhibits the HMGB1-associated
autophagy in osteosarcoma cells during chemotherapy. Tumour Biol.
35:6021–6028. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Wang X, Li J, Yang C, Xing Z, Chen
R and Xu F: HMGB1 knockdown effectively inhibits the progression of
rectal cancer by suppressing HMGB1 expression and promoting
apoptosis of rectal cancer cells. Mol Med Rep. 14:1026–1032. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xia Q, Xu J, Chen H, Gao Y, Gong F, Hu L
and Yang L: Association between an elevated level of HMGB1 and
non-small-cell lung cancer: A meta-analysis and literature review.
OncoTargets Ther. 9:3917–3923. 2016. View Article : Google Scholar
|
|
20
|
Meng Q, Zhao J, Liu H, Zhou G, Zhang W, Xu
X and Zheng M: HMGB1 promotes cellular proliferation and invasion,
suppresses cellular apoptosis in osteosarcoma. Tumour Biol.
35:12265–12274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Aykul S and Martinez-Hackert E:
Determination of half-maximal inhibitory concentration using
biosensor-based protein interaction analysis. Anal Biochem.
508:97–103. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xia J, Yu X, Song X, Li G, Mao X and Zhang
Y: Inhibiting the cytoplasmic location of HMGB1 reverses cisplatin
resistance in human cervical cancer cells. Mol Med Rep. 15:488–494.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rem AI, Oosterhuis JA, Korver JG and van
den Berg TJ: Transscleral laser thermotherapy of hamster Greene
melanoma: Inducing tumour necrosis without scleral damage. Melanoma
Res. 11:503–509. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Uhl M, Saueressig U, van Buiren M, Kontny
U, Niemeyer C, Köhler G, Ilyasov K and Langer M: Osteosarcoma:
Preliminary results of in vivo assessment of tumor necrosis after
chemotherapy with diffusion- and perfusion-weighted magnetic
resonance imaging. Invest Radiol. 41:618–623. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Samimi MA, Mirkheshti N and Pazouki A:
Assessing the percent of necrosis after neoadjuvant chemotherapy
with 24 h infusional cisplatin/3 days Doxorubicin intermittent with
Ifosfamide-Doxorubicin for osteosarcoma. Int J Hematol Oncol Stem
Cell Res. 8:5–8. 2014.PubMed/NCBI
|
|
26
|
Cui Q, Li D, Liu C, Guo J, Liu S, Liu Y,
Wang X and Zeng Y: The significance of MGMT protein detection in
evaluation of osteosarcoma necrosis rate after cisplatin
chemotherapy. Bos J Basic Med Sci. 11:80–83. 2011. View Article : Google Scholar
|
|
27
|
Bajpai J, Gamnagatti S, Kumar R, Sreenivas
V, Sharma MC, Khan SA, Rastogi S, Malhotra A, Safaya R and Bakhshi
S: Role of MRI in osteosarcoma for evaluation and prediction of
chemotherapy response: Correlation with histological necrosis. Ped
Radiol. 41:441–450. 2011. View Article : Google Scholar
|
|
28
|
Blanchard N, Richert L, Coassolo P and
Lave T: Qualitative and quantitative assessment of drug-drug
interaction potential in man, based on Ki, IC50 and inhibitor
concentration. Curr Drug Metab. 5:147–156. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rajkumar T and Yamuna M: Multiple pathways
are involved in drug resistance to doxorubicin in an osteosarcoma
cell line. Anticancer Drugs. 19:257–265. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wan Y, Xu L, Zhuo N, Ge J, Chen G and Lu
XB: The clinical significance of neoadjuvant chemotherapy in
improving the drug resistance of osteosarcoma. Minerva Med.
108:479–481. 2017.PubMed/NCBI
|
|
31
|
Wang Y and Teng JS: Increased multi-drug
resistance and reduced apoptosis in osteosarcoma side population
cells are crucial factors for tumor recurrence. Exp Ther Med.
12:81–86. 2016. View Article : Google Scholar : PubMed/NCBI
|
